Mergers & Acquisitions
Aug. 24, 2016
Cooley, Ropes assist in Pfizer's $14 billion acquisition of Medivation
San Francisco-based Medivation Inc., a biotechnology company responsible for the widely successful prostate cancer treatment Xtandi, has agreed to a $14 billion sale to pharmaceutical giant Pfizer Inc.
Daily Journal Staff Writer
San Francisco-based Medivation Inc., a biotechnology company responsible for the widely successful prostate cancer treatment Xtandi, has agreed to a $14 billion sale to pharmaceutical giant Pfizer Inc.
Cooley LLP and Wachtell, Lipton, Rosen & Katz are advising Medivation. Ropes & Gray LLP is advising Pfizer.
San Francisco partner Jamie K. Leigh is leading the Cool...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In